Phenotypes Associated with This Genotype

Genotype
MGI:4430085

• Allelic Composition: Efnb2^tm2And/Efnb2^tm2And; Tg(CAG-cre/Esr1*)1Egwa/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6 * DBA/2

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

postnatal lethality, complete penetrance ( J:157054 )

• some pups become frail and subsequently die with tamoxifen treatment on first two days postnatal

growth/size/body

postnatal growth retardation ( J:157054 )

• seen with tamoxifen treatment on first two days postnatal

cardiovascular system

abnormal angiogenesis ( J:157054 )

• with tamoxifen treatment, vascular morphology in the dermis is severely affected, with dilatation of the vascular lumen

integument

integument phenotype ( J:157054 )

N • with tamoxifen treatment, infiltration of leukocytes is comparable to untreated controls and is not cause of hypercornification

retarded hair growth ( J:157054 )

• seen at P9 with tamoxifen treatment on first two days postnatal

thin hypodermis ( J:157054 )

• seen at P9 seen with tamoxifen treatment on first two days postnatal

small hair follicles ( J:157054 )

• seen with tamoxifen treatment on first two days postnatal, pups have shorter hair follicles

hyperkeratosis ( J:157054 )

• hypercornification of skin is observed seen at P9 with tamoxifen treatment on first two days postnatal

• with tamoxifen treatment, no difference is detected at P4

thick epidermis ( J:157054 )

• seen at P9 with tamoxifen treatment on first two days postnatal

flaky skin ( J:157054 )

• observed initially by P5 and peaking between 1 and 2 weeks of age with tamoxifen treatment on first two days postnatal

abnormal skin physiology ( J:157054 )

• enhanced proliferation of epidermal progenitor cells is detected with tamoxifen treatment at P1-2